Half-Year 2022 Financial and Clinical Trials Update
Pharma Division sales HY 2022
Product sales Pharmaceuticals Division
Roche
Global
US
Europe
Japan
International
CHFM
% CER
CHFM
% CER
CHFM
% CER
CHFM
% CER
CHFM
% CER
Ocrevus
Perjeta
2,910
17
2,140
11
539
34
231
43
2,061
5
740
Hemlibra
1,826
30
1,098
Tecentriq
1,758
11
951
Actemra/RoActemra
1,455
-10
Herceptin
1,179
-16
Avastin
1,142
-29
MabThera
1,117
-21
Kadcyla
1,074
14
Xolair
1,025
11
1,025
Alecensa
745
19
Ronapreve
609
11
Lucentis
572
-17
TNKase/Activase
559
-10
Evrysdi
500
106
Esbriet
457
-14
Gazyva
349
8
Phesgo
325
241
Pulmozyme
279
0
CellCept
270
-8
Polivy
177
91
Erivedge
131
2
Vabysmo
109
Enspryng
84
132
Rozlytrek
34
54
Cotellic
24
4
1 * * * 5 * 2 6022^
664
263
342
-38
691
-22
415
-17
-10
32
-17
2
155
2
-16
86
-3
192
២ន នី, ៤៩៩សគឺសង់នម់ង់, ≥ ន់៩ ១៨៩ →
8៩ , ៥៩៩ដ៦៖
80
457
-17
360
30
383
19
420
-3
233
-11
116
-53
105
-17
350
10
-
149
7
-86
ទី៩, ៩-៩៩ន៨៩៩
120
744
180
19
188
218
-7
206
174
197
-37
-28
655
-11
263
-13
421
-20
-8
304
-19
23
241
114
467
a
275
77
28
127
៩៩៩ឬទី៖ជនី
152
489
38
83
-2
17
95
-6
28
2
163
338
65
24
403
51
-11
44
-7
29
16
6
4
Gavreto
12
9
58 M
5
199
1 FG 23
∞ *
153
43
11
19
22222 53-58122
34
89
9
52
88
4
-6
1
55
3
ཎྜ༩
102
1
201
18
4
262
9
16
3
Xofluza
4
-145
1 -117
3
Susvimo
2
2
Other Products
1,558
-13
356
-19
175
-21
350
50
-2
12
677
-14
Pharma Division
22,347
3
11,363
4,104
-4
2,202
34
4,678
2
CER Constant Exchange Rates (avg. full year 2021); * over 500%
166View entire presentation